Effect of high-dose plerixafor on CD34⁺ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.

ABSTRACT: Hematopoietic stem cells can be mobilized from healthy donors using single-agent plerixafor without granulocyte colony-stimulating factor and, following allogeneic transplantation, can result in sustained donor-derived hematopoiesis. However, when a single dose of plerixafor is administered at a conventional 240 μg/kg dose, approximately one-third of donors will fail to mobilize the minimally acceptable dose of CD34⁺ cells needed for allogeneic transplantation. We conducted an open-label, randomized trial to assess the safety and activity of high-dose (480 μg/kg) plerixafor in CD34⁺ cell mobilization in healthy donors. Subjects were randomly assigned to receive either a high dose or a conventional dose (240 μg/kg) of plerixafor, given as a single subcutaneous injectio

SUBMITTER: Pantin J 

PROVIDER: S-EPMC5394957 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature